Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)

NCT06351332 is registered in ClinicalTrials.gov with Filipa Lynce, MD as lead sponsor.

NCT NCT06351332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06351332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
Lead sponsor
Filipa Lynce, MD
Phase
Phase 1
Overall status
Terminated
Start date
May 1, 2024
Completion date
February 24, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female, her2-negative breast cancer, hormone receptor negative malignant tumor breast triple, triple negative breast cancer